Pulse Biosciences, Inc. Appoints Liane R. Teplitsky as Chief Operating Officer

Pulse Biosciences, Inc. has appointed Liane R. Teplitsky as its Chief Operating Officer, effective April 8, 2026. Ms. Teplitsky brings extensive experience in leading and scaling medical technology businesses, with a background in electrophysiology, cardiovascular, and digital health. She previously served as CEO of Artedrone and held senior roles at Abbott Laboratories and St. Jude Medical. In her new role, Ms. Teplitsky will oversee the Company's Clinical, Regulatory, Quality, and Commercial functions. Her compensation includes an annual base salary of $525,000, eligibility for a target bonus of 70% of her base salary, and equity awards including a stock option to purchase 700,000 shares and 200,000 restricted stock units, subject to vesting conditions tied to time-based and performance-based objectives. The company also announced an expanded role for Dr. David Kenigsberg as full-time Chief Medical Officer.